Literature DB >> 24511436

Management of depression induced by interferon hepatitis therapies.

Hema Shah1, Snehal Kadia1, Radhika Bawa1, Steven Lippmann1.   

Abstract

OBJECTIVE: Treatment with interferon therapy for hepatitis can induce depression and/or recurrence of affective illness, which could result in cessation of interferon treatment. This article reviews treatment for interferon-induced depression, including antidepressant drugs that may diminish associated symptoms. DATA SOURCES: English-language literature with no date restrictions on the treatment of interferon-induced depression was reviewed via PubMed and MEDLINE using the key words hepatitis, interferon, hepatitis C, interferon-induced depression, pharmacotherapy of interferon-induced depression, and depression prevention. Fourteen of the most pertinent references are cited. DATA EXTRACTION: Escitalopram is the most prominently noted pharmaceutical prescribed for treating mood symptoms in hepatitis patients with interferon-induced depression. Other antidepressant medicines may have utility as well.
RESULTS: Antidepressant drugs can be efficacious in diminishing mood disorders during hepatitis therapies. It remains controversial as to whether antidepressant medications can provide prophylaxis against newly developing interferon-induced depressions in individuals with no past history of a mood disorder.
CONCLUSIONS: Antidepressant medicines can be effective at improving mood in patients undergoing interferon treatment for hepatitis.

Entities:  

Year:  2013        PMID: 24511436      PMCID: PMC3907316          DOI: 10.4088/PCC.12r01487

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN: 2155-7780


  11 in total

1.  Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.

Authors:  Crisanto Diez-Quevedo; Helena Masnou; Ramon Planas; Pere Castellví; Dolors Giménez; Rosa M Morillas; Rocío Martín-Santos; Ricard Navinés; Ricard Solà; Pilar Giner; Mercè Ardèvol; Joan Costa; Moisés Diago; Juan Pretel
Journal:  J Clin Psychiatry       Date:  2010-10-05       Impact factor: 4.384

2.  Major depressive disorder in hepatitis C: an open-label trial of escitalopram.

Authors:  Ondria C Gleason; William R Yates; Michelle A Philipsen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

3.  Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.

Authors:  Martin Schaefer; Rahul Sarkar; Viola Knop; Susanne Effenberger; Astrid Friebe; Loni Heinze; Ulrich Spengler; Thomas Schlaepfer; Jens Reimer; Peter Buggisch; Johann Ockenga; Ralph Link; Michael Rentrop; Hans Weidenbach; Gwendolyn Fromm; Klaus Lieb; Thomas F Baumert; Andreas Heinz; Thomas Discher; Konrad Neumann; Stefan Zeuzem; Thomas Berg
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

Review 4.  Interferon-induced depression: strategies in treatment.

Authors:  Gregory M Asnis; Richard De La Garza
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-06       Impact factor: 5.067

5.  Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.

Authors:  Ondria C Gleason; John C Fucci; William R Yates; Michelle A Philipsen
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

6.  A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.

Authors:  Benjamin J Morasco; Muhamad Aly Rifai; Jennifer M Loftis; David W Indest; James Kelly Moles; Peter Hauser
Journal:  J Affect Disord       Date:  2007-02-09       Impact factor: 4.839

7.  Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.

Authors:  R J de Knegt; G Bezemer; A R Van Gool; J P H Drenth; B E Hansen; H A Droogleever Fortuyn; C J Weegink; M W Hengeveld; H L A Janssen
Journal:  Aliment Pharmacol Ther       Date:  2011-10-17       Impact factor: 8.171

Review 8.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

Authors:  Charles L Raison; Marina Demetrashvili; Lucile Capuron; Andrew H Miller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.

Authors:  C L Raison; B J Woolwine; M F Demetrashvili; A S Borisov; R Weinreib; J P Staab; J M Zajecka; C J Bruno; M A Henderson; J F Reinus; D L Evans; G M Asnis; A H Miller
Journal:  Aliment Pharmacol Ther       Date:  2007-05-15       Impact factor: 8.171

Review 10.  Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C.

Authors:  Catherine C Crone; Geoffrey M Gabriel; Thomas N Wise
Journal:  Cleve Clin J Med       Date:  2004-05       Impact factor: 2.321

View more
  2 in total

1.  Toward ending hepatitis C virus infection: What are the next steps?

Authors:  Geneviève Cadieux; Herveen Sachdeva
Journal:  CMAJ       Date:  2017-04-24       Impact factor: 8.262

2.  Selective serotonin reuptake inhibitors and the risk of hepatocellular carcinoma in hepatitis B virus-infected patients.

Authors:  Chia-Ming Chang; Ming-Shun Hsieh; Tsung-Chieh Yang; Vivian Chia-Rong Hsieh; Jen-Huai Chiang; Hsien-Hao Huang; Chorng-Kuang How; Sung-Yuan Hu; David Hung-Tsang Yen
Journal:  Cancer Manag Res       Date:  2017-11-28       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.